PubMed=9816317
Seliger B., Hohne A., Knuth A., Bernhard H., Ehring B., Tampe R., Huber C.
Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression.
Clin. Cancer Res. 2:1427-1433(1996)

PubMed=12833523; DOI=10.1002/pmic.200300404
Seliger B., Menig M., Lichtenfels R., Atkins D., Bukur J.H., Halder T.M., Kersten M., Harder A., Ackermann A., Beck J., Muehlenweg B., Brenner W., Melchior S., Kellner R., Lottspeich F.
Identification of markers for the selection of patients undergoing renal cell carcinoma-specific immunotherapy.
Proteomics 3:979-990(2003)

CLPUB00420
Bukur J.H.
Characterization of T cell responses against human renal cell carcinoma and identification of HLA-G as a tumor-associated antigen and immune evasion mechanism of renal cell carcinoma.
Thesis PhD (2004); Johannes Gutenberg University Mainz; Mainz; Germany

PubMed=17200335; DOI=10.1158/1078-0432.CCR-06-0824
Seliger B., Fedorushchenko A., Brenner W., Ackermann A., Atkins D., Hanash S.M., Lichtenfels R.
Ubiquitin COOH-terminal hydrolase 1: a biomarker of renal cell carcinoma associated with enhanced tumor cell proliferation and migration.
Clin. Cancer Res. 13:27-37(2007)

PubMed=23696916; PMCID=PMC3657351
Stoehr C.G., Buettner-Herold M., Kamphausen E., Bertz S., Hartmann A., Seliger B.
Comparative expression profiling for human endoplasmic reticulum-resident aminopeptidases 1 and 2 in normal kidney versus distinct renal cell carcinoma subtypes.
Int. J. Clin. Exp. Pathol. 6:998-1008(2013)